Samsung Biologics announced on Wednesday that it participated in the Protein & Antibody Engineering Summit (PEGS) Boston, a global biopharmaceutical technology conference, to expand its connections with international clients.

The company actively showcased its Contract Research and Development Organization (CRDO) capabilities, which enhance the efficiency and success potential of cancer drug development.

PEGS Boston is the world's largest conference for protein and antibody pharmaceuticals, attracting over 2,500 industry experts to discuss cutting-edge biopharmaceutical technologies. The annual event takes place in Boston, Massachusetts, every May, with this year's conference running from May 11-15.

On Tuesday, Samsung Biologics hosted a luncheon presentation titled, Advancing Cancer Drug Development Through Samsung Organoid and Integrated Contract Development Organization (CDO) Capabilities.

Dr. Kim Se-hee, head of the Organoid Technology Group at the CDO Development Center, introduced strategies and expertise to support efficient cancer drug development. Her presentation focused on Samsung Organoid and the development suitability evaluation platform DevelopPick.

Officially launched in June 2022, Samsung Organoid enables pre-validation of cancer drug candidates' efficacy using organoids that closely mimic patient tumors. The service particularly emphasizes screening cancer drug candidates based on patient-derived organoids.

Organoids are three-dimensional cell models that replicate the structure and function of actual organs using stem cells or patient tissues. These models allow researchers to evaluate drug candidates' efficacy and toxicity under conditions similar to the human body, making them a promising next-generation drug development platform.

Samsung Biologics has established nine CDO technology platforms to provide tailored services to clients. These include DevelopPick, the high-concentration formulation development platform S-HighCon, the proprietary cell line platform S-Choice, and the dual antibody platform S-Dual, among others.

James Choi, Vice President of Sales Support at Samsung Biologics, stated it has continuously strengthened the capabilities to maximize the clients' success potential throughout the entire process. Moving forward, it will continue to meet the diverse needs of the clients through the differentiated platforms.

Samsung Biologics announced on Wednesday that it participated in the Protein & Antibody En …

Samsung Biologics Highlights CRDO and Organoid Platforms at PEGS Boston